ClinicalTrials.gg

Program

HS-10541

A development code.

In Hansoh Pharmaceutical Group's pipeline, KRAS G12C. Its studies are led by Hansoh Pharmaceutical Group.

Furthest: phase 1, since May 14, 20261 company-led study, 1 open or runningNext primary completion: Jun 30, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group11 open or runningphase 1since May 14, 2026May 14, 2026Jun 30, 2029phase 1 · NCT07615413
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10541 (KRAS G12C), phase 1, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2026First study: phase 1 study in KRAS G12C Mutation Advanced Solid TumorFirst studyNCT07615413 · 636 planned

Ahead

  1. Jun 30, 2029Primary completion: phase 1 study in KRAS G12C Mutation Advanced Solid TumorNCT07615413

TargetBeta

“KRAS G12C”the company's pipeline, read by Claude · source

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07615413KRAS G12C Mutation Advanced Solid Tumor1Not yet recruitingJun 30, 2029636

How it is read

Names in the registry

  • “HS-10541”, 1 entry

Codes read as this program: HS10541.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.